Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Supernus to Present at Two Investor Conferences in September



Supernus to Present at Two Investor Conferences in September

ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
the Company's management will present an overview of the Company at the
following investor conferences in September 2013:

Rodman & Renshaw:
Presentation Date: Monday, September 9
Time: 11:40am ET
Place:  Millennium Broadway Hotel, NY
 
Stifel Nicolaus Weisel:
Presentation Date: Thursday, September 12
Time: 1:30pm ET
Place: Four Seasons Hotel, Boston, MA

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved
product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company
is also developing several product candidates in psychiatry to address large
market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

CONTACT: Jack A. Khattar, President and CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement